Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2010
10/21/2010US20100266713 Aqueous ophthalmic compositions containing anionic therapeutic agents
10/21/2010US20100266711 Thienobenzodiazepine modulators of d1 receptor, d2 receptor, and/or 5-ht2 receptor
10/21/2010US20100266710 Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions
10/21/2010US20100266706 Oral particulate antitumor preparation
10/21/2010US20100266705 Nanoparticulate megestrol formulations
10/21/2010US20100266703 Novel powder and its method of manufacture
10/21/2010US20100266702 Particles containing an active agent in the form of a co-precipitate
10/21/2010US20100266701 Anti-misuse microparticulate oral drug form
10/21/2010US20100266699 Pharmaceutical Suspensions and Related Methods
10/21/2010US20100266696 Organic Compounds
10/21/2010US20100266695 Multivalent clustering targeting strategy for drug carriers
10/21/2010US20100266693 Controlled release local anesthetic comprising a biologically active non-sulfated glycosaminoglycan matrix
10/21/2010US20100266692 Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
10/21/2010US20100266691 Agents and Methods to Stimulate Bone Healing
10/21/2010US20100266686 Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
10/21/2010US20100266684 Method and composition for administering an nmda receptor antagonist to a subject
10/21/2010US20100266683 New self emulsifying drug delivery system
10/21/2010US20100266682 Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
10/21/2010US20100266681 Fatty acid alcohols
10/21/2010US20100266680 Treatment of Cancer Using TLR3 Agonists
10/21/2010US20100266679 Crystalline modifications of n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (l)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof
10/21/2010US20100266676 Nanocapsules with a liquid lipid core charged with water-soluble or water-dispersible active agents
10/21/2010US20100266674 L-oddc prodrugs for cancer
10/21/2010US20100266671 Device and Method for Treating Dermal Tissue
10/21/2010US20100266670 Transdermally absorptive preparation
10/21/2010US20100266669 Multi-zone films
10/21/2010US20100266668 Manufacturing Dissolvable Dosage Forms
10/21/2010US20100266667 Mucosal bioadhesive slow release carrier for delivering active principles
10/21/2010US20100266664 Devices And Methods For Ophthalmic Drug Delivery
10/21/2010US20100266659 Implantable devices formed on non-fouling methacrylate or acrylate polymers
10/21/2010US20100266657 Preformed drug-eluting device to be affixed to an anterior spinal plate
10/21/2010US20100266655 Sustained delivery formulations of risperidone compounds
10/21/2010US20100266654 Medical composition including an extracellular matrix particulate
10/21/2010US20100266645 Pharmaceutical compositions
10/21/2010US20100266634 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
10/21/2010US20100266630 Recombinant MVA virus, and the use thereof
10/21/2010US20100266621 Methods and systems for treating cell proliferation disorders with psoralen derivatives
10/21/2010US20100266618 Compositions and methods for augmenting activity of oncolytic viruses
10/21/2010US20100266615 D1-1 nucleic acids, polypeptides and related methods
10/21/2010US20100266592 Therapeutic antennapedia-antibody molecules and methods of use thereof
10/21/2010US20100266588 Breast Cancer Susceptibility Gene GT198 and Uses Thereof
10/21/2010US20100266581 Compositions and methods for modulating s-nitrosogluthione reductase
10/21/2010US20100266580 Translocation and mutant tnk1 kinase in human lymphoma
10/21/2010US20100266579 Treatment of inflammatory diseases
10/21/2010US20100266578 Treatment and diagnostic methods for hypersensitive disorders
10/21/2010US20100266574 Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
10/21/2010US20100266571 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
10/21/2010US20100266570 Dimeric derivatives of artemisinin and application in anticancer therapy
10/21/2010US20100266565 Combinational Chemotherapy Treatment
10/21/2010US20100266548 LPS-Responsive CHS1/Beige-Like Anchor Gene and Therapeutic Applications Thereof
10/21/2010US20100266547 Methods and compositions for treatment of interferon-resistant tumors
10/21/2010US20100266544 Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
10/21/2010US20100266543 Linked dibenzimidazole antivirals
10/21/2010US20100266540 Drug class for the treatment of cancer
10/21/2010US20100266539 Chemokine receptor antagonist and medical use thereof
10/21/2010US20100266538 Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
10/21/2010US20100266537 Hcv inhibitors
10/21/2010US20100266535 Compounds Having CRTH2 Antagonist Activity
10/21/2010US20100266528 Systemic Administration of Colony Stimulating Factors to Treat Amyloid Associated Disorders
10/21/2010US20100266527 Anti-microbial polymers and their compositions
10/21/2010US20100266526 Combination therapy for treating hypercholesterolemia
10/21/2010US20100266524 Composition Comprising Silicone Oil or Oils Structured With Compolymers Carrying Greater Than 70% Long Chain Alkyl Group
10/21/2010US20100266523 Compositions containing flavanoid polyphenol derivatives, and applications thereof in controlling diseases and ageing of living organisms
10/21/2010US20100266516 Personal care composition
10/21/2010US20100266511 Pharmaceutical foam
10/21/2010US20100266509 Heteroaryl amide analogues as p2x7 antagonists
10/21/2010US20100266503 Breast Cancer Methods, Medicaments and Agents
10/21/2010US20100266491 System for targeted delivery of therapeutic agents
10/21/2010US20100264055 Portable Powder Delivery System and Method
10/21/2010DE69229688C5 Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten Containing ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
10/21/2010DE202006020892U1 Partialglyceride als Schmiermittel für pharmazeutische Zusammensetzungen enthaltend Thieno[3,2-c]pyridin-Derivate Partial glycerides as a lubricant for pharmaceutical compositions containing thieno [3,2-c] pyridine derivatives
10/21/2010DE102009002417A1 Verwendung organomodifizierter, im Siliconteil verzweigter Siloxane zur Herstellung kosmetischer oder pharmazeutischer Zusammensetzungen Using organically modified in Silicon part branched siloxanes for producing cosmetic or pharmaceutical compositions
10/21/2010CA2795611A1 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
10/21/2010CA2767044A1 Drug delivery system and methods of use
10/21/2010CA2761752A1 Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters
10/21/2010CA2761064A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
10/21/2010CA2759098A1 Methods and compositions for the treatment of medical conditions involving cellular programming
10/21/2010CA2759025A1 Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
10/21/2010CA2759011A1 Antiadhesion agents
10/21/2010CA2758974A1 Method of treating disorders associated with protein kinase ck2 activity
10/21/2010CA2758948A1 Method for the induction of a reward response by modulation of dopaminergic systems in the central nervous system
10/21/2010CA2758937A1 Sensor-based wireless communication systems using compressive sampling
10/21/2010CA2758934A1 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
10/21/2010CA2758929A1 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
10/21/2010CA2758927A1 Modulation of inflammatory responses by factor xi
10/21/2010CA2758918A1 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
10/21/2010CA2758916A1 Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same
10/21/2010CA2758883A1 Stabilization of radiopharmaceutical compositions using ascorbic acid
10/21/2010CA2758858A1 Aqueous ophthalmic compositions containing anionic therapeutic agents
10/21/2010CA2758855A1 Compounds for the treatment of mitochondrial diseases
10/21/2010CA2758854A1 High fiber nutritional emulsions for blood glucose control
10/21/2010CA2758852A1 Antiepileptic, hypocholesterolemic and neuroprotective compound
10/21/2010CA2758847A1 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound
10/21/2010CA2758835A1 Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis and/or pruritus
10/21/2010CA2758823A1 Protein phosphatase 2a-activating agents
10/21/2010CA2758820A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
10/21/2010CA2758774A1 Monoamine reuptake inhibitors
10/21/2010CA2758772A1 Indole derivative modulators of the alpha 7 nachr
10/21/2010CA2758764A1 Method for on-demand contraception using levonorgestrel or norgestrel
10/21/2010CA2758756A1 Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
1 ... 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 ... 7860